EPHEDRINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ephedrine, and when can generic versions of Ephedrine launch?
Ephedrine is a drug marketed by Amneal, Caplin, Civica, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Mankind Pharma, Ph Health, Renew Pharms, Sagent Pharms Inc, Sandoz, Xiromed, and Zydus Pharms. and is included in nineteen NDAs. There are two patents protecting this drug.
The generic ingredient in EPHEDRINE is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ephedrine
A generic version of EPHEDRINE was approved as ephedrine sulfate by SANDOZ on August 23rd, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EPHEDRINE?
- What are the global sales for EPHEDRINE?
- What is Average Wholesale Price for EPHEDRINE?
Summary for EPHEDRINE
| US Patents: | 0 |
| Applicants: | 15 |
| NDAs: | 19 |
| Drug Prices: | Drug price information for EPHEDRINE |
| DailyMed Link: | EPHEDRINE at DailyMed |
US Patents and Regulatory Information for EPHEDRINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 212932-001 | Oct 23, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Renew Pharms | EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208609-001 | Mar 1, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Fresenius Kabi Usa | EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 209646-001 | Aug 4, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Dr Reddys | EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 212649-001 | Oct 3, 2020 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hikma | EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 217721-001 | Oct 11, 2024 | AP3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
